<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198506</url>
  </required_header>
  <id_info>
    <org_study_id>KKS-256</org_study_id>
    <secondary_id>2019-001770-29</secondary_id>
    <nct_id>NCT04198506</nct_id>
  </id_info>
  <brief_title>Viral Load Guided Immunosuppression After Lung Transplantation</brief_title>
  <acronym>VIGILung</acronym>
  <official_title>Viral Load Guided Immunosuppression After Lung Transplantation, an Open-label, Randomized, Controlled, Parallel-group, Multicenter Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philipps University Marburg Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philipps University Marburg Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The VIGILung study is an open-label, randomized, multicenter trial in lung transplant
      recipients to investigate the safety and efficacy of personalized immunosuppression guided by
      DNA monitoring of Torque-Teno-Virus (TTV). The aim of the study is to investigate an
      individual adaptation of the calcineurin inhibitor tacrolimus (tailored calcineurin inhibitor
      dosing) by a non-invasive biomarker (TTV viral load in whole blood) compared to conventional
      calcineurin inhibitor dosing. Indicator for toxicity will be the glomerular filtration rate
      (GFR), which will be estimated using the CKD-EPI formula. 250 patients (age ≥ 18 years) with
      21 to 42 days after de novo lung transplantation (bilateral or combined) will be screened as
      possible subjects eligible for the study. N = 144 patients have to be randomized in two study
      arms. In Arm 1 tacrolimus doses will be adapted according to the tacrolimus blood level
      (conventional therapeutic drug monitoring - TDM) and additionally depending on TTV viral
      load. In Arm 2 tacrolimus doses will be adapted according to TDM.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ΔGFR change of the glomerular filtration rate GFR</measure>
    <time_frame>Between randomization and 12 months thereafter</time_frame>
    <description>The primary efficacy endpoint ΔGFR is defined as the change of the glomerular filtration rate GFR between randomization and 12 months thereafter. GFR will be estimated using the CKD-EPI formula.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GFR (CKD-EPI)</measure>
    <time_frame>1 and 2 months after transplantation (screening visits) and 0, 3, 6, 9 and 12 months after randomization</time_frame>
    <description>Glomerular filtration rate (the Chronic Kidney Disease Epidemiology Collaboration - CKD-EPI) formula</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GFR (Cystatin)</measure>
    <time_frame>Screening visits and 0, 3, 6, 9 and 12 months after randomization</time_frame>
    <description>Glomerular filtration rate (Cystatin)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of biopsy-proven acute cellular rejection (grade A1 or higher)</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of biopsy-proven lymphocytic bronchitis (grade B1R or higher)</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of cytomegalovirus (CMV)-infections and CMV-disease episodes</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of community-acquired respiratory viral infections (CARV)</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of fungal and bacterial infections</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unscheduled or emergency hospitalizations</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICU admissions</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>Screening visits and 0, 3, 6, 9 and 12 months after randomization</time_frame>
    <description>European Quality of Life 5 Dimensions - EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New or progressive malignancy</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median tacrolimus trough levels</measure>
    <time_frame>Screening visits and 0, 3, 6, 9 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tacrolimus dose</measure>
    <time_frame>Screening visits and 0, 3, 6, 9 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of changes (increase or decrease) in target trough levels of tacrolimus</measure>
    <time_frame>Screening visits and 0, 3, 6, 9 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exercise capacity (6-Min Walk Test - 6MWT)</measure>
    <time_frame>At randomization and 12 months thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4-Lymphocytes counts</measure>
    <time_frame>0, 6 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor specific antibodies</measure>
    <time_frame>0, 6 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 in % best value</measure>
    <time_frame>Screening visits and 0, 3, 6, 9 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic lung allograft dysfunction</measure>
    <time_frame>Between randomization and 12 months thereafter</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IgG-level</measure>
    <time_frame>0, 6 and 12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of rescue immunotherapy (defined by the use of ATG, Rituximab, Alemtuzumab, plasma exchange, immunoadsorption)</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or re-do transplantation</measure>
    <time_frame>12 months after randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Transplantation Lung</condition>
  <arm_group>
    <arm_group_label>Tailored tacrolimus dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM) and additionally depending on TTV viral load.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional tacrolimus dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tailored tacrolimus dosing</intervention_name>
    <description>Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring -TDM) and additionally depending on TTV viral load.</description>
    <arm_group_label>Tailored tacrolimus dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Conventional tacrolimus dosing</intervention_name>
    <description>Tacrolimus doses will be adapted according to tacrolimus blood level (conventional therapeutic drug monitoring - TDM).</description>
    <arm_group_label>Conventional tacrolimus dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients 21 to 42 days after de novo lung transplantation (bilateral or combined)

          2. Age ≥ 18 years

          3. Tacrolimus based immunosuppression

          4. Written informed consent

          5. Detectable TTV load at randomization (&gt;2,7 log 10)

          6. Negative serum pregnancy test in women of childbearing potential

          7. Women of childbearing capacity must agree to maintain highly effective methods of
             contraception by practicing abstinence or by using at least two methods of birth
             control from the date of consent through the end of the study. If abstinence is not
             practiced, a combination of hormonal contraceptive (oral, injectable or implants) and
             a barrier method (condom, diaphragm with a vaginal spermicidal agent) has to be used

        Exclusion Criteria:

          1. History or high-risk of obstructive airway complications after lung transplantation

          2. Respiratory failure (need for oxygen therapy or ventilation at screening after lung
             transplantation)

          3. Inability to undergo transbronchial biopsy

          4. Advanced kidney failure (GFR CKD-EPI &lt;30 ml/min/1.73m²) at inclusion and/or current
             renal replacement therapy at inclusion or randomization

          5. Advanced liver cirrhosis (CHILD-Pugh Score C) after lung transplantation

          6. Fluctuating tacrolimus drug levels (less than 20% in target range after
             transplantation)

          7. Symptoms of significant mental illness and with inability to cooperate or communicate
             with the investigator

          8. Unlikeliness to comply with the study requirements

          9. HIV positivity

         10. Evidence of unsolved drug or alcohol addiction

         11. Breastfeeding women

         12. Simultaneous participation in other clinical trials if not permitted by the steering
             committee
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Gottlieb, Prof. MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für Pneumologie OE 6870, Medizinische Hochschule Hannover (MHH)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jens Gottlieb, Prof. MD</last_name>
    <phone>+49 (0) 511-532-4601</phone>
    <email>gottlieb.jens@mh-hannover.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinik für Pneumologie OE 6870, Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Jens Gottlieb, Prof. MD</last_name>
      <phone>+49 (0) 511-532-4601</phone>
      <email>gottlieb.jens@mh-hannover.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 5, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>lung transplantation</keyword>
  <keyword>dosing immunosuppression</keyword>
  <keyword>toxicity</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

